InnoCare Pharma (HKG:9969, SHA:688428) said the 80 mg once daily dose of its BTK inhibitor, Orelabrutinib, for the treatment of relapsing-remitting multiple sclerosis, was selected for phase 3 progressive multiple sclerosis studies following a demonstration of efficacy and safety profile.
The company's phase 2 results were released at the 10th annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum. These results will be presented as the on-site poster at the forum on Thursday, a Wednesday bourse filing said.
Orelabrutinib is a selective brain-penetrant BTK inhibitor that inhibits B cell, microglia, and macrophage activation in the central nervous system along with inhibiting macrophage activation.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。